1Parring HH, Persson F, Lewis JB, et al. The combination of aliskiren, a direct renin inhibitor, and losartan in patients with type 2 diabetes and nephropathy[J]. New Engl J Med, 2008,358(23) :2433-2446.
2McMurray JJV, Pitt B, Latini R, et al, Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure [J]. Circ Heart Fail,2008,1(1) : 17-24.
3Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the di rect renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy[J]. Circulation, 2009,119 (4) :530-537.
4Jordan J, Engeli S, Boye SW, et al. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension[J]. Hyper tension,2007,49(5) :1047-1055.
5Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension[J]. J Renin Angiotensin Aldosterone Syst,2007,8(4) : 190-198.
6Schmieder RE, Philipp T, Guerediaga J, et al. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: subanalysis of a 52-week, randomized, double-blind trial[J]. J Hypertens,2009,27(7) : 1493-1501.
7Oh BH, Mitchell J, Herron JER, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension[J]. J Am Coll Cardiol,2007,49(11) : 1157-1163.
8Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihy- pertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide[J]. Circulation, 2009,27,119 (3): 417- 425.
9Andersen K, Weinberger M H, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial[J]. J Hypertens, 2008,26 (3) : 589-599.
10Oparil S, Yarrows, S, Patel S, et al. Efficacy and safety of corn bined use of aliskiren and valsartan in patients with hypertension a randomised, double-blind trial[J]. Lancet, 2007,370 (9583) : 221 229.
二级参考文献18
1[1]Gross F,Lazar J,Orth H.Inhibition of the renin-angiotensinogen reaction by pepstin[J].Science,1971,175:656.
2[2]Cumin F,Evin G,Fehrentz JA,et al.Inhibition of human renin by synthetic peptides derived from its prosegment[J].J Biol Chem,1985,260:9154-9157.
3[3]Wood JM,Gulati N,Forgiarini P,et al.Effects of a specific and long-acting renin inhibitor in the marmoset[J].Hypertension,1985,7:653-658.
4[4]Wood JM,Cumin F,Maibaum J.Pharmacology of renin inhibitors and their application to the treatment of hypertention[J].Pharmacol Ther,1994,61:325-344.
5[5]Maibaum J,Feldman DL.Renin inhibitors as novel treatment for cardiovascular disease[J].Expert Opin Ther Patents,2003,13:589-603.
6[6]Wood JM,Criscione L,de Gasparo M,et al.CGP 38560:orally active,low-molecular-weight renin inhibitor with high potency and specificity[J].J Cardiovasc Pharmacol,1989,14:221-226.
7[7]Lefevre G,Duval M,Poncin A.Direct micro-radioimmunoassay of the new renin inhibitor CGP60536[J].J Immunoassay,2000,21:65-84.
8[8]Rahuel J,Rasetti V,Maibaum J,et al.Structure-based drug design:The discovery of novel nonpeptide orally active inhibitors of human renin[J].Chem Biol,2000,7:493-504.
9[9]Dieterle W,Corynen S,Mann J.Effects of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects[J].Br J Clin Pharmacol,2004,58:433-436.
10[10]Nussberger J,Wuerzner G,Jensen C,et al.AngiotensinⅡ suppression in humans by the orally active renin inhibitor aliskiren (SPP 100).Comparison with enalapril[J].Hypertension,2002,39:e1-8.
同被引文献33
1Pedelty L, Goreliek PB. Management of hypertension and cere- brovaseular disease in the elderly[J]. Am J Med, 2008,121 (8 Sup- pI) :S23-31.
2HareI Z, Gilbert C, Wald R, et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin sys- tem on hyperkalaemia and acute kidney injury: systematic review and meta-analysis[J]. BMJ ,2012,344 :e42.
3Gilbert CJ, Gomes T, Mamdani MM, et al. No increase in ad- verse events during aliskiren use among ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers[J]. Can J Cardiol.2013.29(5) :586-591.
4Riecioni G. Aliskiren in the treatment of hypertension and organ damage[J]. Cardiovasc Ther, 2011,29 ( 1 ) : 77-87.
5White WB, Bresalier R, Kaplan AP. et al. Saety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension[J]. J C]in Hypertens(Greenwich) ,2010,12(10) :765-775.
6Jadad AR, Moore RA, Carroll D, et aI. Assessing the quality of reports of randomized clinical trials: is blinding necessary? [J]. Control Clin Trials, 1996,17 ( 1 ) : 1-12.
7I.ittlejohn TW 3rd, Trenkwalder P, Hollanders G, et al. Long- term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension[J]. Curr Med Res Opin,2009,25(4) :951-959.
8Flack JM, Yadao AM, Purkayastha D, et al. Comparison of the effects of aliskiren/valsartan in combination versus valsartan alonein patients with stage 2 hypertension[J]. J Am Soc Hypertens, 2012,6(2) :142-151.
9Basile J, Babazadeh S, Lillestol M, et al. Comparison of aliskiren/hydrochlorothiazide combination therapy with hydro- chlorothiazide monotherapy in older patients with stage 2 systolic hypertension: results of the ACTION study[J]. J Clin Hypertens (Greenwich), 2011,13(3) : 162-169.
10Black HR, Weinberger MH, Purkayastha D, et al. Comparative efficacy and safety of combination aliskiren/amlodipine and amlo- dipine monotherapy in African Americans with stage 2 hyperten sion[J]. J Clin Hypertens(Greenwich), 2011,13 (8) :571-581.
